Biostatistics & Study Design Support: Sample Size, SAP, Survival Analysis & Regression

High-Impact Journals

Interesting topics

Biostatistics & Study Design Support: Sample Size, SAP, Survival Analysis & Regression

Biostatistics is the basis for the design of studies, the analysis of clinical data, and the interpretation of results. Designing a good study involves more than simply choosing the statistical method to use after collecting the data. It includes sample size calculations, statistical analyses, survival analyses, regressions, missing data plans, and sensitivity analyses before even starting a study. Researchers may also seek biostatistics support services, study design consulting, and biostatistician for researchers to ensure appropriate statistical planning from the beginning.

In clinical and biomedical research, statistical planning increasingly emphasizes clearly defining the treatment effect of interest within an estimand framework, selecting an appropriate study design, prespecifying the statistical analysis, adjusting for appropriate covariates, and evaluating whether conclusions remain robust under alternative assumptions. ICH E9(R1) emphasizes the connection between the research question, estimand, study design, data collection, analysis, sensitivity analysis, and interpretation. [1]

Research Question → Estimand → Study Design → Endpoint → Sample Size → Statistical Analysis Plan (SAP) → Analysis → Sensitivity Analysis → Interpretation

1. Why Biostatistics Matters in Study Design

Biostatistics plays a major role in translating a scientific question into a rigorous statistical study. Poor statistical planning can result in inadequate sample sizes, unrealistic assumptions, imprecise estimates, insufficient statistical power, inappropriate analyses, and conclusions that do not adequately address the research question. [2]

Important factors include:

The main objective of the research study
Adequate study design
The estimand and treatment effect of interest
Sample size and statistical power
Pre-determination of population and methods of analysis
Missing data and sensitivity analysis

According to the statistical principles of ICH E9, statistics is an important part of clinical trial design and analysis.

2. Sample Size and Power Calculation

Sample size calculation determines how many participants are required to detect a clinically meaningful effect with an acceptable probability of achieving statistical significance. Power analysis estimates the probability of detecting a specified effect under assumptions. However, statistical power should not be considered separately from clinical relevance. The assumed effect size should be justified based on what would represent a clinically meaningful difference.

The calculation depends on factors such as:

Parameter	Role in Sample Size Planning
Effect size	Magnitude of the difference or association to detect
Significance level	Controls the probability of a Type I error
Statistical power	Probability of detecting a true effect
Outcome variability	Influences precision of the estimated effect
Allocation ratio	Determines participants assigned to study groups
Expected dropout	Accounts for participants who may not complete the study

Sample-size planning should be linked to the primary endpoint and planned analysis, rather than performed independently from the study design.

3. Statistical Analysis Plan (SAP)

The Statistical Analysis Plan (SAP) describes in advance how the study data will be analyzed. A well-developed SAP helps distinguish confirmatory analyses from exploratory analyses and reduces the opportunity to select analytical methods after observing the results. Statistical analysis plan (SAP) services and SAP writing support can assist researchers in developing a structured analysis plan aligned with the study objectives. [3]

A typical SAP should cover the following issues:

analysis population
principal and secondary endpoints
analysis methods
adjustment for covariates
approach to handling missing data
subgroup analyses
sensitivity analyses
multiplicity issues

In clinical trials, analyses should be planned beforehand without considering the outcome of the study, or in case of blinding of investigators, at least before the blinding is broken. The recent FDA guidance on overall survival stresses this point.

4. Survival Analysis for Time-to-Event Outcomes

Survival analysis is used when the response variable is the time to the occurrence of an event such as death, recurrence of the disease, failure of treatment, and admission to hospital. Clinical trial statistics may incorporate survival analysis when evaluating time-to-event outcomes in clinical research.

Unlike ordinary regression techniques, survival analysis considers censoring in which the event does not occur, or the subject is lost to observation during the study period.

Common methods include:

Method	Primary Application
Kaplan–Meier analysis	Estimating survival probabilities over time
Log-rank test	Comparing survival distributions
Cox proportional hazards model	Estimating treatment or covariate effects
Parametric survival models	Modelling specified survival distributions
Time-dependent models	Handling covariates that change over time

5. Model assumptions and endpoint dependence

Assumptions of the model and dependency of endpoints. The survival analysis approach needs to be dependent thethe definition of the endpoint, estimand, the nature of censoring, follow-up schedule, and assumptions made by the statistical model used.

For instance, the Cox proportional hazards model depends on the proportional hazards assumption. Failure to satisfy this assumption implies that one hazard ratio cannot summarize treatment effect across the follow-up period.

Other options that may depend on the research question at hand could be:

Time-dependent effects of treatment
Stratified Cox models
Restricted mean survival time
Parametric survival models
Other pre-specified time-to-event analyses.

The FDA “Approaches to Assessment of Overall Survival in Oncology Clinical Trials” is a draft guidance document for August 2025 and is specific on approaches for prespecified assessment of overall survival in randomized oncology trials. It is marked as a “Draft– Not for implementation.”

6. Regression Analysis in Clinical Research

Regression analysis allows researchers to examine relationships between outcomes and explanatory variables while accounting for relevant covariates. Regression analysis is therefore an important component of research data analysis plan development and clinical research statistics. [4]

Common approaches include:

Research Outcome	Typical Regression Approach
Continuous outcome	Linear regression
Binary outcome	Logistic regression
Count outcome	Poisson or negative binomial regression
Time-to-event outcome	Cox regression
Repeated measurements	Mixed-effects or longitudinal models

Regression modelling can improve precision when important prognostic variables are appropriately prespecified. FDA guidance published in 2026 also highlights covariate adjustment to improve statistical efficiency and precision in randomized clinical trials.

7. Current Trends in Biostatistical Study Design

Modern biostatistics is shifting its focus from traditional hypothesis testing to more holistic and flexible analysis approaches. [5]

Estimand-Based Analysis: The estimand approach clearly articulates what treatment effect should be estimated in a clinical trial. This approach links the research question to the outcome, population, treatment intervention, and management of intercurrent events.
Bayesian Clinical Trial Methods: The FDA released “Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry” in January 2026. This document focuses on the application of Bayesian methodology in primary inference, interim analysis, adaptive designs, dose selection, and prior information.
Adaptive Trial Designs: Adaptive designs permit modifications in certain features of a trial based on accrued evidence without compromising statistical validity. The ICH E20 draft guidance released in 2025 discusses planning, execution, analysis, and interpretation of adaptive clinical trials.
Data-Driven and Computational Biostatistics: Modern statistical processes increasingly involve the use of computational tools, reproducible programming, machine learning, and data quality control. Such an approach can be used in addition to proper statistical design and clinical experience.

8. Common Statistical Challenges

Some of the issues that researchers might face while conducting their studies include the following:

Small sample sizes or unrealistic assumptions
Missing or partial data
Assumption violations
Multiple endpoints or subgroups
Overfitting in regression models
Bad handling of censoring
Changing the statistical approach after-the-fact

Multiplicity becomes an important concern when there are many endpoints under consideration since it increases the chance of false positives. FDA guidelines recommend predefining the right strategies for dealing with multiple endpoints.

9. Integrated Biostatistical Workflow

Research Question → Estimand → Study Design → Endpoint → Sample Size → SAP → Analysis → Sensitivity Analysis → Interpretation

This integrated approach helps maintain a clear connection between the scientific objective and the statistical analysis.

Why this sequence matters

10. Practices for Reliable Statistical Analysis

Steps that should be undertaken by researchers include:

Determination of goals and end points before analysis.
Basing the sample size determination on justified assumptions.
Conducting the SAP before the study results.
Evaluation of the model assumptions and the sensitivity analyses.
Presentation of the effect sizes along with the confidence interval rather than just using p-values.

The objective is not to seek statistical significance, but valid, reproducible, and interpretable results. [6]

Connect with us to explore how we can support you in maintaining academic integrity and enhancing the visibility of your research across the world!

Conclusion

Biostatistics plays an essential role in good quality clinical and biomedical research, starting from study design to results interpretation. Sample size calculation, SAP creation, survival analysis, and regression analysis are among several complementary approaches that will help address the research questions using proper statistical techniques.

Some recent developments such as the estimand concept, Bayesian approach, adaptive clinical trials, better covariates adjustment, and prespecification are adding to this statistical basis for clinical research. An effectively developed biostatistical approach will assist the researchers in obtaining statistically sound, transparent, and clinically meaningful results.

Biostatistics & Study Design Support: Sample Size, SAP, Survival Analysis & Regression. Our Pubrica consultants are here to guide you. [Get Expert Publishing Support] or [Schedule a Free Consultation]

Frequently Asked Questions (FAQs)

1. What is the role of biostatistics in clinical research?

Biostatistics supports study design, sample size calculation, statistical analysis, interpretation of results, and evidence-based decision-making in clinical and biomedical research.

2. Why is sample size calculation important?

Sample size calculation helps determine the number of participants needed to detect a clinically meaningful effect with adequate statistical power while avoiding unnecessarily large or underpowered studies.

3. What is a Statistical Analysis Plan (SAP)?

A Statistical Analysis Plan (SAP) is a pre-specified document describing how study data will be analysed. It typically covers endpoints, analysis populations, statistical methods, missing data, subgroup analyses, sensitivity analyses, and multiplicity.

4. When is survival analysis used?

Survival analysis is used when the outcome involves time until an event occurs, such as death, disease recurrence, treatment failure, or hospital admission. Common methods include Kaplan–Meier analysis and Cox regression.

5. How does regression analysis help clinical researchers?

Regression analysis examines relationships between outcomes and explanatory variables while allowing researchers to account for relevant covariates. The appropriate model depends on whether the outcome is continuous, binary, count-based, or time-to-event.

6. When should researchers consider biostatistics support services?

Researchers can consider biostatistics support services from the study-design stage through data analysis and interpretation. Support may include study design consulting, sample size calculation, power analysis, SAP writing support, survival analysis, regression analysis, and development of a research data analysis plan.

References

Perera, M., & Dwivedi, A. K. (2020). Statistical issues and methods in designing and analyzing survival studies. Cancer reports (Hoboken, N.J.), 3(4), e1176. https://doi.org/10.1002/cnr2.1176
Zapf, A., Rauch, G., & Kieser, M. (2020). Why do you need a biostatistician?. BMC medical research methodology, 20(1), 23. https://doi.org/10.1186/s12874-020-0916-4
Watson H. J. (2025). A Statistical Analysis Plan Template for Observational Studies: Promoting Quality and Rigor in Research. Journal of statistical theory and practice, 19(4), 10.1007/s42519-025-00504-9. https://doi.org/10.1007/s42519-025-00504-9
Zapf, A., Wiessner, C., & König, I. R. (2024). Regression Analyses and Their Particularities in Observational Studies—Part 32 of a Series on Evaluation of Scientific Publications. Deutsches Arzteblatt international, 121(4), 128–134. https://doi.org/10.3238/arztebl.m2023
Yardibi, F., Chen, C., Aladag, C. H., & Kose, O. (2025). Current Trends and Future Directions of Statistical Methods in Medical Research: A Scientometric Analysis. Journal of evaluation in clinical practice, 31(6), e70257. https://doi.org/10.1111/jep.70257
Mishra, P., Pandey, C. M., Singh, U., Keshri, A., & Sabaretnam, M. (2019). Selection of appropriate statistical methods for data analysis. Annals of cardiac anaesthesia, 22(3), 297–301. https://doi.org/10.4103/aca.ACA_24